Swiss approve insurance cover for Novartis, Gilead cell therapies
The Swiss government approved on
Friday health insurance coverage for CAR-T cell therapies from
Novartis and Gilead Sciences, which can cost
hundreds of thousands of dollars per patient.
Friday health insurance coverage for CAR-T cell therapies from
Novartis and Gilead Sciences, which can cost
hundreds of thousands of dollars per patient.
Posted by Reuters
